Synlogic, Inc. (SYBX)
| Market Cap | 160.79M |
| Revenue (ttm) | 246,000 |
| Net Income (ttm) | -57.27M |
| Shares Out | 52.05M |
| EPS (ttm) | -1.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 139,241 |
| Open | 3.15 |
| Previous Close | 3.18 |
| Day's Range | 3.15 - 3.23 |
| 52-Week Range | 1.78 - 5.11 |
| Beta | 1.71 |
| Analysts | Buy |
| Price Target | 10.00 (+212.5%) |
| Est. Earnings Date | Nov 4, 2021 |
About SYBX
Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumo...
Financial Performance
In 2020, Synlogic's revenue was $545,000, a decrease of -75.49% compared to the previous year's $2.22 million. Losses were -$59.17 million, 15.2% more than in 2019.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for Synlogic stock is "Buy." The 12-month stock price forecast is 10.00, which is an increase of 212.50% from the latest price.
News
Synlogic Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of ...
Synlogic Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has com...
Why Are Synlogic Shares Moving Higher Premarket Monday?
Synlogic Inc (NASDAQ: SYBX) has announced data from clinical studies evaluating SYNB1618 and SYNB1934 for phenylketonuria (PKU). PKU is a rare genetic disease that manifests at birth and is characterize...
Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phen...
CAMBRIDGE, Mass., Sept. 20, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced positive ...
Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting
CAMBRIDGE, Mass., Sept. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it w...
Synlogic Presents at Global PKU Patient Meeting
CAMBRIDGE, Mass., Sept. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the de...
Synlogic, Inc. (SYBX) Reports Q2 Loss, Tops Revenue Estimates
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 3.45% and 23.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Synlogic Reports Second Quarter Financial Results and Provides Business Update
CAMBRIDGE, Mass., Aug. 12, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial r...
Synlogic Announces Second Quarter 2021 Conference Call & Participation in Upcoming Banking Conference
CAMBRIDGE, Mass., Aug. 5, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company...
Will Synlogic, Inc. (SYBX) Report Negative Q2 Earnings? What You Should Know
Synlogic, Inc. (SYBX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Synlogic Publishes Papers in Nature Journals Demonstrating Proof-of-Mechanism and Potential of Synthetic Biotic Platf...
CAMBRIDGE, Mass., July 22, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today the public...
Synlogic's (SYBX) Begins Phase I Study for PKU Treatment
Synlogic (SYBX) initiates phase I study of SYNB1934, a synthetic biotic candidate to treat PKU. The drug is an evolved strain of SYNB1618, another PKU candidate currently undergoing phase II study.
Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketon...
CAMBRIDGE, Mass., July 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it ha...
Synlogic, Roche Ink Research Pact For Inflammatory Bowel Disease Therapy
Synlogic Inc (NASDAQ: SYBX) has entered into a research collaboration agreement with Roche Holding AG (OTC: RHHBY) for the discovery of Synthetic Biotic medicine for inflammatory bowel disease (IBD). Un...
Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease
CAMBRIDGE, Mass., June 17, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today that it ha...
Synlogic Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB88...
CAMBRIDGE, Mass., June 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the dev...
Synlogic Reminds Stockholders of 2021 Annual General Meeting Details
CAMBRIDGE, Mass., June 3, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, reminds stockholders that i...
Synlogic to Present at Upcoming Virtual Banking and Industry Conference
CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife ...
Synlogic Presents Data at Digestive Disease Week (DDW) on a Novel Approach for the Treatment of Inflammatory Bowel Di...
CAMBRIDGE, Mass., May 23, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on an ...
Synlogic Reports First Quarter Financial Results and Provides Business Update
CAMBRIDGE, Mass., May 13, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial re...
Synlogic Announces First Quarter 2021 Conference Call & Webcast
CAMBRIDGE, Mass., May 6, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company ...
3 Penny Stocks That Wall Street Wants You To Buy Now
Penny stocks are very risky, which is why they have such low prices. Many of the companies in this risky part of the market will go bankrupt.
Penny Stocks To Buy According To Analysts With Price Targets Up to 341%
Analysts say these penny stocks are a buy right now & have bullish price targets to boot. The post Penny Stocks To Buy According To Analysts With Price Targets Up to 341% appeared first on Penny Stocks ...
Synlogic Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., April 16, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of i...